3-phenylallylideneaminoguanidine | 5382-85-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-phenylallylideneaminoguanidine
• 英文别名: Zimtaldehyd-guanylhydrazon；Cinnamaldehyde guanylhydrazone；2-(cinnamylideneamino)guanidine
• CAS: 5382-85-4
• 化学式: C₁₀H₁₂N₄
• mdl: MFCD00989408
• 分子量: 188.232
• InChiKey: ZIXIIJQSFSAZOL-UHFFFAOYSA-N

物化性质

• 沸点：
  333.4±35.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  76.8
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-phenylallylideneaminoguanidine 、 乙酰乙酸乙酯 、 柠檬醛 在 Cu(II)-tyrosinase 作用下， 以 neat (no solvent) 为溶剂， 反应 0.08h， 以83%的产率得到4-(2,6-dimethyl-hepta-1,5-dienyl)-6-methyl-2-[(3-phenylallylidene)-hydrazono]-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid ethyl ester
  参考文献：
  名称：

  绿色催化剂Cu(II)-酶介导的2-嘧啶胺的环保合成作为潜在的灭蚊剂对库蚊蚊子的杀幼剂和对非目标水生物种的毒性研究

  摘要：

  2-嘧啶胺衍生物的新型一锅多组分合成可以通过绿色化学实现，使用 Cu(II)-酪氨酸酶 (Cu-Tyr) 作为催化剂。该方法提供温和的反应条件和高的衍生物收率。我们以这种方式合成了几种化合物并评估了它们的杀幼虫和拒食活性。在合成的衍生物中，化合物3的中位致死剂量 (LD 50 ) 为 21.43 µg/mL ，与化合物1a-m和2以及对照物hydantocidin相比，对库蚊具有高度活性。化合物1j、1d和1e对C. quinquefasciatus的 LD 50值分别为 78.46、78.59 和 79.54 µg/mL。在拒食筛选中，化合物1j、1l和2在 24 小时内对100 µg/mL 的Oreochromis mossambicus产生 100% 死亡率，其中毒性确定为 24 小时时死鱼和活鱼种的数量 (%)。相比之下，化合物1a-f、1i、1m和3对O. mossambicus

  DOI：

  10.1016/j.bioorg.2021.104697
• 作为产物：
  描述：

  肼甲酰亚胺酰胺一氯化氢 、 肉桂醛 在 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 2.17h， 以98%的产率得到3-phenylallylideneaminoguanidine
  参考文献：
  名称：

  ALKYLIDENE AMINOGUANIDINE AND SALT THEREOF, MODIFYING COMPOSITION, MODIFIED RUBBER FOR TIRE, RUBBER COMPOSITION FOR TIRE, AND TIRE

  摘要：

  提供的化合物由以下式表示： 其中X是一种酸，用于与胍位形成盐；而R1和R2分别独立地选自以下组合：氢原子、C1-18烷基、环烷基、芳基、烷基芳基和烯基，每种基团可选地具有一个或多个含有硫原子、氮原子或氧原子的取代基。

  公开号：

  US20170129850A1

文献信息

• Synthesis, Antileishmanial Activity and in silico Studies of Aminoguanidine Hydrazones (AGH) and Thiosemicarbazones (TSC) Against Leishmania chagasi Amastigotes
  作者：Thiago M. de Aquino、Paulo H. B. França、Érica E. E. S. Rodrigues、Igor. J.S. Nascimento、Paulo F. S. Santos-Júnior、Pedro G. V. Aquino、Mariana S. Santos、Aline C. Queiroz、Morgana V. Araújo、Magna S. Alexandre-Moreira、Raiza R. L. Rodrigues、Klinger A. F. Rodrigues、Johnnatan D. Freitas、Jacques Bricard、Mario R. Meneghetti、Jean-Jacques Bourguignon、Martine Schmitt、Edeildo F. da Silva-Júnior、João X. de Araújo-Júnior

  DOI：10.2174/1573406417666210216154428

  日期：2022.2

  Leishmaniasis is a worldwide health problem, highly endemic in developing countries. Among the four main clinical forms of the disease, visceral leishmaniasis is the most severe, fatal in 95% of cases. The undesired side-effects from first-line chemotherapy and the reported drug resistance search for effective drugs that can replace or supplement those currently used an urgent need. Aminoguanidine hydrazones (AGH's) have been explored for exhibiting a diverse spectrum of biological activities, in particular the antileishmanial activity of MGBG. The bioisosteres thiosemicarbazones (TSC's) offer a similar biological activity diversity, including antiprotozoal effects against Leishmania species and Trypanosoma cruzi.

  Considering the impact of leishmaniasis worldwide, this work aimed to design, synthesize, and perform a screening upon L. chagasi amastigotes and for the cytotoxicity of the small "in-house" library of both AGH and TSC derivatives and their structurally-related compounds.

  A set of AGH's (3-7), TSC's (9, 10), and semicarbazones (11) were initially synthesized. Subsequently, different semi-constrained analogs were designed and also prepared, including thiazolidines (12), dihydrothiazines (13), imidazolines (15), pyrimidines (16, 18) azines (19, 20), and benzotriazepinones (23-25). All intermediates and target compounds were obtained with satisfactory yields and exhibited spectral data consistent with their structures. All final compounds were evaluated against L. chagasi amastigotes and J774.A1 cell line. Molecular docking was performed towards trypanothione reductase using GOLD® software.

  The AGH's 3i, 4a, and 5d, and the TSC's 9i, 9k, and 9o were selected as valuable hits. These compounds presented antileishmanial activity compared with pentamidine, showing IC50 values ranged from 0.6 to 7.27 μM, maximal effects up to 55.3%, and satisfactory SI values (ranged from 11 to 87). On the other hand, most of the resulting semi-constrained analogs were found cytotoxic or presented reduced antileishmanial activity. In general, TSC class is more promising than its isosteric AGH analogs, and the beneficial aromatic substituent effects are not similar in both series. In silico studies have suggested that these hits are capable of inhibiting the trypanothione reductase from the amastigote forms.

  The promising antileishmanial activity of three AGH’s and three TSC’s was characterized. These compounds presented antileishmanial activity compared with PTD, showing IC50 values ranged from 0.6 to 7.27 μM, and satisfactory SI values. Further pharmacological assays involving other Leishmania strains are under progress, which will help to choose the best hits for in vivo experiments.

  背景：利什曼病是全球性健康问题，在发展中国家高度流行。在该病的四种主要临床形式中，内脏利什曼病是最严重的，95%的病例会致命。由于一线化疗药物的不良副作用和报道的药物耐药性，迫切需要寻找可以替代或补充当前使用的有效药物。氨基胍脒肼酮（AGH）已被探索用于展示多样的生物活性，特别是MGBG的抗利什曼病活性。生物同功异构体硫脲半胱氨酮（TSC）提供类似的生物活性多样性，包括对利什曼病和克氏锥虫的抗原虫效应。 目的：考虑到利什曼病在全球范围内的影响，本研究旨在设计、合成并对L. chagasi阿马斯蒂果虫进行筛选，以及对小型“内部”AGH和TSC衍生物及其结构相关化合物的细胞毒性进行评估。 方法：首先合成了一组AGH（3-7）、TSC（9, 10）和半胱氨酮（11）。随后，设计并制备了不同的半约束类似物，包括噻唑烷（12）、二氢噻嗪（13）、咪唑烷（15）、嘧啶（16, 18）、吲哚烷（19, 20）和苯并三唑环酮（23-25）。所有中间体和目标化合物均以满意的收率获得，并展示了与其结构一致的光谱数据。所有最终化合物均对L. chagasi阿马斯蒂果虫和J774.A1细胞系进行了评估。使用GOLD®软件对其进行了针对巯基还原酶的分子对接。 结果：AGH的3i、4a和5d以及TSC的9i、9k和9o被选为有价值的命中物。这些化合物与五环胺相比具有抗利什曼病活性，IC50值范围从0.6到7.27μM，最大效果高达55.3％，满意的SI值（范围从11到87）。另一方面，大多数结果的半约束类似物被发现具有细胞毒性或具有降低的抗利什曼病活性。总体而言，TSC类比其同功异构AGH类更有前景，而有益的芳香族取代作用在两个系列中并不相似。计算机模拟研究表明这些命中物能够抑制阿马斯蒂果虫的巯基还原酶。 结论：三种AGH和三种TSC的有前景的抗利什曼病活性得到了表征。这些化合物与PTD相比具有抗利什曼病活性，IC50值范围从0.6到7.27μM，SI值满意。正在进行涉及其他利什曼病菌株的进一步药理学评估，这将有助于选择最佳的命中物进行体内实验。
• Aralkylaminoguanidines and related compounds
  作者：John B. Bream、Claude W. Picard、Trevor G. White、Hans Lauener

  DOI：10.1021/jm00300a007

  日期：1970.11
• METHODS FOR TREATING PROTOZOAN INFECTIONS
  申请人：Neoculi Pty Ltd

  公开号：EP3188722A1

  公开（公告）日：2017-07-12
• [EN] METHODS FOR TREATING PROTOZOAN INFECTIONS<br/>[FR] MÉTHODES DE TRAITEMENT D'INFECTIONS À PROTOZOAIRES
  申请人：NEOCULI PTY LTD

  公开号：WO2016033635A1

  公开（公告）日：2016-03-10

  The invention provides compounds of Formula (I), and their use in methods for treating or preventing a protozoan infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in the manufacture of a medicament for the treatment of a protozoan infection in a subject. The invention further provides a medical device when used in a method of treating or preventing a protozoan infection in a subject and to a medical device comprising the composition of the invention.
• ALKYLIDENE AMINOGUANIDINE AND SALT THEREOF, MODIFYING COMPOSITION, MODIFIED RUBBER FOR TIRE, RUBBER COMPOSITION FOR TIRE, AND TIRE
  申请人：Mitsubishi Gas Chemical Company, Inc.

  公开号：US20170129850A1

  公开（公告）日：2017-05-11

  Provided is a compound represented by formula (1): wherein X is an acid to form a salt with a guanidine site; and R 1 and R 2 are each independently any selected from the group consisting of a hydrogen atom, a C 1-18 alkyl group, a cycloalkyl group, an aryl group, an alkylaryl group, and an alkenyl group, each of the groups optionally having one or more substituents each containing a sulfur atom, a nitrogen atom, or an oxygen atom.

  提供的化合物由以下式表示： 其中X是一种酸，用于与胍位形成盐；而R1和R2分别独立地选自以下组合：氢原子、C1-18烷基、环烷基、芳基、烷基芳基和烯基，每种基团可选地具有一个或多个含有硫原子、氮原子或氧原子的取代基。